Comparative Evaluation of the In Vitro Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant Pseudomonas aeruginosa

Antimicrob Agents Chemother. 2020 Feb 21;64(3):e01669-19. doi: 10.1128/AAC.01669-19. Print 2020 Feb 21.

Abstract

The in vitro activity of WCK 5222 (cefepime-zidebactam) was compared to that of several available combination therapies among 30 clinical carbapenem-resistant Pseudomonas aeruginosa (CRP) strains using gradient diffusion strips. The combinations included nonsusceptible β-lactams (cefepime, ceftolozane-tazobactam, and meropenem) with amikacin and fosfomycin. WCK 5222 MICs ranged from 2 to 32 mg/liter, and 97% were ≤16 mg/liter, while 105/146 (72%) combinations demonstrated inhibition below established susceptibility breakpoints. WCK 5222 monotherapy may be preferred over the combinations assessed for CRP infections.

Keywords: Pseudomonas aeruginosa; WCK 5222; beta-lactams; carbapenem resistant; gradient diffusion; synergy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amikacin / pharmacology
  • Anti-Bacterial Agents / pharmacology*
  • Azabicyclo Compounds / pharmacology
  • Cephalosporins / pharmacology
  • Cyclooctanes / pharmacology
  • Drug Resistance, Multiple, Bacterial
  • Fosfomycin / pharmacology
  • Microbial Sensitivity Tests
  • Pseudomonas aeruginosa / drug effects*

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Cephalosporins
  • Cyclooctanes
  • WCK 5222
  • Fosfomycin
  • Amikacin